TNFRSF4 and neoplasm: Beyond checkpoint inhibition, several other therapeutic interventions have been reported to complement the anti-tumor activity of OX40 stimulation, including other immune-stimulatory mAbs, recombinant IL-2, immunization, radiotherapy, intratumoral TLR ligands, chemotherapeutics, and more (26, 53, 54, 63, 65, 70, 71, 80, 153, 187–192).